Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pegylated interferon alfa-CCR5 antagonist combination HIV therapy

A technology of PEGylation and antagonists, applied in antiviral agents, antibodies, drug combinations, etc., can solve problems such as multidrug resistance and inability to eradicate HIV-1

Inactive Publication Date: 2002-05-15
SCHERING AG
View PDF30 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these multidrug regimens fail to eradicate HIV-1, and long-term treatment generally leads to multidrug resistance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0086] As used herein, the following terms are defined as follows unless otherwise stated.

[0087] Alkyl (including alkyl moieties of alkoxy, alkylamino and dialkylamino) means straight and branched carbon chains containing 1 to 6 carbon atoms.

[0088] Alkenyl means C with 1 or 2 unsaturated bonds 2 -C 6 carbon chain, provided that the two unsaturated bonds are not adjacent to each other.

[0089] Substituted phenyl refers to phenyl that can be substituted at any available position on the benzene ring.

[0090] Acyl means having the formula alkyl-C(O)-, aryl-C(O)-, aralkyl-C(O)-, (C 3 -C 7 ) Cycloalkyl-C(O)-, (C 3 -C 7 ) cycloalkyl-(C 1 -C 6 ) radicals of carboxylic acids of alkyl-C(O)- and heteroaryl-C(O)-, wherein alkyl and heteroaryl are as defined herein; aryl is R 12 -Phenyl or R 12 -naphthyl; and aralkyl is aryl-(C 1 -C 6 ) alkyl, wherein aryl is as defined above.

[0091] Heteroaryl means a cyclic aryl group of 5 or 6 atoms or a bicyclic group of 11-12 at...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The use of a pegylated interferon-alfa and a CCR5 antagonist, further in association with at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with an anti-HIV-1 drug therapy, e.g., HAART, for preparation of a medicament for the treatment of HIV-1 infections as well as HIV-1 infections as well as HIV-1 and HCV co-infections in treatment-naive as well as treatment-experienced adult and pediatric patients are disclosed.

Description

Background of the invention [0001] The present invention relates to the application of pegylated interferon-alpha and CCR5 antagonist in the preparation of medicines for treating HIV-1 infection and co-infection of HIV-1 and HCV in patients. The treatment comprises administering a therapeutically effective amount of pegylated interferon-alpha sufficient to reduce HIV-1-RNA in combination with a therapeutically effective amount of a CCR5 antagonist. [0002] The global health crisis caused by Human Immunodeficiency Virus-1 (“HIV-1”), the cause of Acquired Immunodeficiency Syndrome (AIDS), has been established and recent advances in drug therapy have successfully slowed Despite the development of AIDS, it is still necessary to find safer, more effective and low-cost ways to control this virus. [0003] The CCR5 gene has been reported to play a role in resistance to HIV infection. HIV infection begins with attachment of the virus to target cell membranes through the interaction...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K47/48A61K31/4545A61K31/496A61K31/506A61K31/7052A61K38/00A61K38/21A61K39/395A61K45/00A61P31/14A61P31/18A61P43/00
CPCA61K38/212A61P31/14A61P31/18A61P43/00A61K2300/00
Inventor M·A·劳林
Owner SCHERING AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com